BlackRock, Inc. (BLK) 13D/13G Filings for Verve Therapeutics, Inc. (VERV)

BlackRock, Inc. 13D and 13G filings for Verve Therapeutics, Inc.:

  • Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
  • Shares have been adjusted for stock splits.
Time period
Reported
DateTime
Transaction
Date
Type Company
Symbol
Filed By
Symbol
Shares Owned
% Owned
Shares Vs. Prev Report View
2025-04-17
5:40 pm
Sale
2025-03-31 13G Verve Therapeutics, Inc.
VERV
BLACKROCK INC
BLK
6,177,751
7.000%
-1,098,596decrease
(-15.10%)
Filing
2025-04-17
09:35 am
Purchase
2025-03-31 13G Verve Therapeutics, Inc.
VERV
BLACKROCK INC
BLK
6,177,751
7.000%
6,177,751increase
(New Position)
Filing
2024-11-08
2:17 pm
Unchanged
2024-09-30 13G Verve Therapeutics, Inc.
VERV
BLACKROCK INC
BLK
7,276,347
8.600%
0
(Unchanged)
Filing
2024-10-22
3:24 pm
Purchase
2024-09-30 13G Verve Therapeutics, Inc.
VERV
BLACKROCK INC
BLK
7,276,347
8.600%
2,840,866increase
(+64.05%)
Filing
2024-01-29
5:25 pm
Purchase
2023-12-31 13G Verve Therapeutics, Inc.
VERV
BLACKROCK INC
BLK
4,435,481
5.600%
4,435,481increase
(New Position)
Filing